


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.04%
-4.57%
-2.15%
JNJ
Johnson & Johnson
$204.79
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Outperform the market
JNJ Price Performance
$201.62 (+1.57%)
$191.08 (+7.18%)
$174.42 (+17.41%)
$145.27 (+40.97%)
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
JNJ Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
BLTE
160.18
+0.48%
ANNX
5.10
-2.30%
SNDX
20.34
+0.59%
REGN
776.54
+1.74%
PFE
25.43
+1.03%
What is JNJ current stock price?
What are JNJ stock strengths?
What is JNJ Risk Level?
What is JNJ market cap and volume?
What is JNJ current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.04%
-4.57%
-2.15%
JNJ
Johnson & Johnson
Current Price
$204.79
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Outperform the market
Linked to JNJ
BLTE
160.18
+0.48%
ANNX
5.10
-2.30%
SNDX
20.34
+0.59%
REGN
776.54
+1.74%
PFE
25.43
+1.03%

JNJ Price Performance
$201.62 (+1.57%)
$191.08 (+7.18%)
$174.42 (+17.41%)
$145.27 (+40.97%)
JNJ Analysts Opinion
JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
JNJ Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Average key support and resistance price levels
JNJ Stock IQ
JNJ Latest Analysis
Noteworthy ETF Inflows: USMV JNJ CB MCK. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares MSCI USA Min Vol Factor ETF (Symbol: USMV) where we have detected an approximate $206.8 million dollar inflow -- thats a 0.9% increase week
Today
Alumis Stock Catapults More Than 110% As Biotech Takes On J&J Protagonist In Psoriasis. Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against J&.J in psoriasis.The post Alumis Stock Catapults More Than 110% As Biotech Takes On J&.J Protagonist In Psoriasis appeared first on Investor'.s Business Daily.
Today
J&J succeeds in mid-stage trial for SLE therapy.
Today
Alumis Stock Catapults More Than 100% As Biotech Takes On J&J Protagonist In Psoriasis. Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against J&.J in psoriasis.The post Alumis Stock Catapults More Than 100% As Biotech Takes On J&.J Protagonist In Psoriasis appeared first on Investor'.s Business Daily.
Today
J&J Seeks EMA Nod For TECVAYLI- DARZALEX Combo In Relapsed Multiple Myeloma . (RTTNews) - Johnson & Johnson (JNJ) has submitted a Type II variation application to the European Medicines Agency seeking approval for the use of TECVAYLI in combination with DARZALEX subcutaneous formulation for adults with relapsed or refractory multiple myeloma who have recei
Today
Johnson & Johnsons Phase 2b JASMINE Study Of Nipocalimab In SLE Meets Primary Endpoint . (RTTNews) - Johnson & Johnson (JNJ) on Tuesday reported positive topline results from the Phase 2b JASMINE study of nipocalimab in adults with systemic lupus erythematosus (SLE).
Today
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note. In the closing of the recent trading day Johnson & Johnson (JNJ) stood at $204.31 denoting a -1.47% move from the preceding trading day.
Mon Jan 5, 2026
Johnson & Johnson declares $1.30 dividend.
Fri Jan 2, 2026
Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?. The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So is it worth buying the stock?
Wed Dec 31, 2025
Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar. Johnson &. Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26 Johnson &. Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its [….]
Tue Dec 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.